Physician profile
Triptpal Sanghera
NPI 1598211823
$866.00
in general payments reported to CMS, 2019-2025
19 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.93 · 2021: $55.04 · 2022: $185 · 2023: $172 · 2024: $190 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $589.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $168.02 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Intuitive Surgical, INC. | $84.12 | 2023 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $80.71 | 2024-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $74.10 | 2021-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $69.23 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.45 | 2022-2025 | |
| Glaxosmithkline, LLC. | $43.14 | 2021-2025 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $42.69 | 2022 | |
| Abbvie INC. | $42.00 | 2019-2024 | |
| Exact Sciences Corporation | $38.51 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $32.20 | 2021-2022 | |
| Dexcom, INC. | $30.68 | 2021-2023 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $20.92 | 2025 | Symbravo |
| Mylan Specialty L.P. | $20.00 | 2024 | Yupelri |
| Bioventus LLC | $17.57 | 2025 | Durolane |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $14.99 | 2023 | Seglentis |
| E.R. Squibb & Sons, L.L.C. | $14.30 | 2022 | |
| Astellas Pharma US INC | $14.17 | 2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Triptpal Sanghera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.